As per DelveInsight, the diagnosed prevalent cases of Systemic Lupus Erythematosus were found to be 651,965 in the 7MM in 2020, with the USA accounting for the maximum prevalence. Moreover, the epidemiological analysis estimated that mild SLE cases were higher followed by moderate SLE prevalent cases with severe SLE accounting for the least number of SLE prevalent cases.
Currently, the unmet medical need for effective therapy with a favorable safety profile creates a significant challenge in the Systemic Lupus Erythematosus Treatment Market . Complicated pathogenesis of the disease and low clinical outcomes add an extra burden.
However, to overcome the existing challenges at the therapeutics front, leading pharma and biotech companies such as UCB, Biogen, Eli Lilly and Company, Incyte, ImmuPharma, Roche, and others are diligently involved in the development of potential therapies for the SLE treatment, which are expected to enter the market in the near future. With the numerous ongoing clinical trials, the Systemic Lupus Erythematosus Treatment Market is expected to grow significantly in the coming years owing to the launch of the emerging therapies.
Read More: Systemic Lupus Erythematosus Treatment Market